25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Merck & Company Inc
Buy, Hold or Sell?

Let's analyze Merck together

I guess you are interested in Merck & Company Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Merck & Company Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Merck & Company Inc

I send you an email if I find something interesting about Merck & Company Inc.

1. Quick Overview

1.1. Quick analysis of Merck (30 sec.)










1.2. What can you expect buying and holding a share of Merck? (30 sec.)

How much money do you get?

How much money do you get?
$3.01
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$17.20
Expected worth in 1 year
$19.15
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
$4.96
Return On Investment
4.8%

For what price can you sell your share?

Current Price per Share
$103.50
Expected price per share
$97.24 - $131.30
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Merck (5 min.)




Live pricePrice per Share (EOD)
$103.50

2.2. Growth of Merck (5 min.)




Is Merck growing?

Current yearPrevious yearGrowGrow %
How rich?$43.6b$42.8b-$2b-5.1%

How much money is Merck making?

Current yearPrevious yearGrowGrow %
Making money$3.4b-$1.5b$5b145.9%
Net Profit Margin21.3%-10.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Merck (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Merck?

Welcome investor! Merck's management wants to use your money to grow the business. In return you get a share of Merck.

First you should know what it really means to hold a share of Merck. And how you can make/lose money.

Speculation

The Price per Share of Merck is $103.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Merck.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Merck, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $17.20. Based on the TTM, the Book Value Change Per Share is $0.49 per quarter. Based on the YOY, the Book Value Change Per Share is $7.63 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.75 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Merck.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps2.152.1%1.351.3%-0.62-0.6%0.700.7%0.700.7%
Usd Book Value Change Per Share1.271.2%0.490.5%7.637.4%2.872.8%2.872.8%
Usd Dividend Per Share0.780.8%0.750.7%0.740.7%0.750.7%0.750.7%
Usd Total Gains Per Share2.052.0%1.241.2%8.378.1%3.623.5%3.623.5%
Usd Price Per Share129.30-118.38-110.26-115.67-115.67-
Price to Earnings Ratio15.04--2.46-5.79-0.29-0.29-
Price-to-Total Gains Ratio62.98-10.11--20.34--0.04--0.04-
Price to Book Ratio7.52-7.37-6.62-7.12-7.12-
Price-to-Total Gains Ratio62.98-10.11--20.34--0.04--0.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share103.5
Number of shares9
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.750.75
Usd Book Value Change Per Share0.492.87
Usd Total Gains Per Share1.243.62
Gains per Quarter (9 shares)11.1532.55
Gains per Year (9 shares)44.61130.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
127183527103120
254358054206250
3815312581310380
410870170108413510
513688215135516640
6163105260162619770
7190123305189722900
82171403502168261030
92441583952439291160
1027117544027010321290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%4.02.00.066.7%4.02.00.066.7%4.02.00.066.7%4.02.00.066.7%
Book Value Change Per Share3.01.00.075.0%4.02.00.066.7%4.02.00.066.7%4.02.00.066.7%4.02.00.066.7%
Dividend per Share4.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Total Gains per Share3.01.00.075.0%4.02.00.066.7%4.02.00.066.7%4.02.00.066.7%4.02.00.066.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Merck & Company Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2710.486+161%7.628-83%2.867-56%2.867-56%
Book Value Per Share--17.20116.060+7%16.870+2%16.330+5%16.330+5%
Current Ratio--1.4661.339+10%1.363+8%1.347+9%1.347+9%
Debt To Asset Ratio--0.6120.623-2%0.597+3%0.6140%0.6140%
Debt To Equity Ratio--1.5831.657-4%1.499+6%1.604-1%1.604-1%
Dividend Per Share--0.7830.753+4%0.743+5%0.750+4%0.750+4%
Enterprise Value--259119352550.400233160445152.000+11%216587337034.680+20%227636075779.560+14%227636075779.560+14%
Eps--2.1501.353+59%-0.621+129%0.695+209%0.695+209%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--4.0213.729+8%3.667+10%3.708+8%3.708+8%
Free Cash Flow Per Share--1.9101.295+47%0.605+216%1.065+79%1.065+79%
Free Cash Flow To Equity Per Share--2.3890.496+382%2.085+15%1.026+133%1.026+133%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap262633333248.000-25%328101352550.400300378945152.000+9%279896337034.680+17%293551409112.893+12%293551409112.893+12%
Net Profit Margin--0.3390.213+59%-0.101+130%0.109+212%0.109+212%
Operating Margin----0%0.131-100%0.044-100%0.044-100%
Operating Ratio--0.8520.999-15%1.305-35%1.101-23%1.101-23%
Pb Ratio6.017-25%7.5177.373+2%6.622+14%7.123+6%7.123+6%
Pe Ratio12.036-25%15.037-2.463+116%5.788+160%0.287+5132%0.287+5132%
Price Per Share103.500-25%129.300118.375+9%110.260+17%115.670+12%115.670+12%
Price To Free Cash Flow Ratio13.549-25%16.926-7.203+143%114.308-85%33.301-49%33.301-49%
Price To Total Gains Ratio50.409-25%62.97510.113+523%-20.339+132%-0.038+100%-0.038+100%
Quick Ratio--0.4490.443+1%0.519-14%0.468-4%0.468-4%
Return On Assets--0.0480.032+53%-0.016+132%0.016+205%0.016+205%
Return On Equity--0.1250.081+54%-0.047+138%0.039+225%0.039+225%
Total Gains Per Share--2.0531.239+66%8.371-75%3.616-43%3.616-43%
Usd Book Value--43648000000.00040751750000.000+7%42823500000.000+2%41442333333.333+5%41442333333.333+5%
Usd Book Value Change Per Share--1.2710.486+161%7.628-83%2.867-56%2.867-56%
Usd Book Value Per Share--17.20116.060+7%16.870+2%16.330+5%16.330+5%
Usd Dividend Per Share--0.7830.753+4%0.743+5%0.750+4%0.750+4%
Usd Enterprise Value--259119352550.400233160445152.000+11%216587337034.680+20%227636075779.560+14%227636075779.560+14%
Usd Eps--2.1501.353+59%-0.621+129%0.695+209%0.695+209%
Usd Free Cash Flow--4846000000.0003286750000.000+47%1535500000.000+216%2703000000.000+79%2703000000.000+79%
Usd Free Cash Flow Per Share--1.9101.295+47%0.605+216%1.065+79%1.065+79%
Usd Free Cash Flow To Equity Per Share--2.3890.496+382%2.085+15%1.026+133%1.026+133%
Usd Market Cap262633333248.000-25%328101352550.400300378945152.000+9%279896337034.680+17%293551409112.893+12%293551409112.893+12%
Usd Price Per Share103.500-25%129.300118.375+9%110.260+17%115.670+12%115.670+12%
Usd Profit--5455000000.0003434000000.000+59%-1577000000.000+129%1763666666.667+209%1763666666.667+209%
Usd Revenue--16112000000.00015619750000.000+3%14761000000.000+9%15333500000.000+5%15333500000.000+5%
Usd Total Gains Per Share--2.0531.239+66%8.371-75%3.616-43%3.616-43%
 EOD+4 -4MRQTTM+33 -4YOY+27 -115Y+29 -910Y+29 -9

3.3 Fundamental Score

Let's check the fundamental score of Merck & Company Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.036
Price to Book Ratio (EOD)Between0-16.017
Net Profit Margin (MRQ)Greater than00.339
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.449
Current Ratio (MRQ)Greater than11.466
Debt to Asset Ratio (MRQ)Less than10.612
Debt to Equity Ratio (MRQ)Less than11.583
Return on Equity (MRQ)Greater than0.150.125
Return on Assets (MRQ)Greater than0.050.048
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Merck & Company Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5010.404
Ma 20Greater thanMa 50129.910
Ma 50Greater thanMa 100129.660
Ma 100Greater thanMa 200124.688
OpenGreater thanClose101.600
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Merck & Company Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Fundamental data was last updated by Penke on 2024-12-07 02:32:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Merck earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Merck to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 33.9% means that $0.34 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Merck & Company Inc:

  • The MRQ is 33.9%. The company is making a huge profit. +2
  • The TTM is 21.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ33.9%TTM21.3%+12.5%
TTM21.3%YOY-10.1%+31.5%
TTM21.3%5Y10.9%+10.5%
5Y10.9%10Y10.9%0.0%
4.3.1.2. Return on Assets

Shows how efficient Merck is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Merck to the Drug Manufacturers - General industry mean.
  • 4.8% Return on Assets means that Merck generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Merck & Company Inc:

  • The MRQ is 4.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.8%TTM3.2%+1.7%
TTM3.2%YOY-1.6%+4.7%
TTM3.2%5Y1.6%+1.6%
5Y1.6%10Y1.6%0.0%
4.3.1.3. Return on Equity

Shows how efficient Merck is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Merck to the Drug Manufacturers - General industry mean.
  • 12.5% Return on Equity means Merck generated $0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Merck & Company Inc:

  • The MRQ is 12.5%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 8.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ12.5%TTM8.1%+4.4%
TTM8.1%YOY-4.7%+12.8%
TTM8.1%5Y3.9%+4.3%
5Y3.9%10Y3.9%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Merck & Company Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Merck is operating .

  • Measures how much profit Merck makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Merck to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Merck & Company Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY13.1%-13.1%
TTM-5Y4.4%-4.4%
5Y4.4%10Y4.4%0.0%
4.3.2.2. Operating Ratio

Measures how efficient Merck is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.85 means that the operating costs are $0.85 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Merck & Company Inc:

  • The MRQ is 0.852. The company is less efficient in keeping operating costs low.
  • The TTM is 0.999. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.852TTM0.999-0.147
TTM0.999YOY1.305-0.306
TTM0.9995Y1.101-0.102
5Y1.10110Y1.1010.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Merck & Company Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Merck is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.47 means the company has $1.47 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Merck & Company Inc:

  • The MRQ is 1.466. The company is just able to pay all its short-term debts.
  • The TTM is 1.339. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.466TTM1.339+0.127
TTM1.339YOY1.363-0.024
TTM1.3395Y1.347-0.008
5Y1.34710Y1.3470.000
4.4.3.2. Quick Ratio

Measures if Merck is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Merck to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.45 means the company can pay off $0.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Merck & Company Inc:

  • The MRQ is 0.449. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.443. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.449TTM0.443+0.005
TTM0.443YOY0.519-0.076
TTM0.4435Y0.468-0.025
5Y0.46810Y0.4680.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Merck & Company Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Merck assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Merck to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.61 means that Merck assets are financed with 61.2% credit (debt) and the remaining percentage (100% - 61.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Merck & Company Inc:

  • The MRQ is 0.612. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.623. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.612TTM0.623-0.010
TTM0.623YOY0.597+0.026
TTM0.6235Y0.614+0.009
5Y0.61410Y0.6140.000
4.5.4.2. Debt to Equity Ratio

Measures if Merck is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Merck to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 158.3% means that company has $1.58 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Merck & Company Inc:

  • The MRQ is 1.583. The company is just able to pay all its debts with equity.
  • The TTM is 1.657. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.583TTM1.657-0.074
TTM1.657YOY1.499+0.157
TTM1.6575Y1.604+0.052
5Y1.60410Y1.6040.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Merck generates.

  • Above 15 is considered overpriced but always compare Merck to the Drug Manufacturers - General industry mean.
  • A PE ratio of 15.04 means the investor is paying $15.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Merck & Company Inc:

  • The EOD is 12.036. Based on the earnings, the company is underpriced. +1
  • The MRQ is 15.037. Based on the earnings, the company is fair priced.
  • The TTM is -2.463. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD12.036MRQ15.037-3.000
MRQ15.037TTM-2.463+17.500
TTM-2.463YOY5.788-8.251
TTM-2.4635Y0.287-2.750
5Y0.28710Y0.2870.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Merck & Company Inc:

  • The EOD is 13.549. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 16.926. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -7.203. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.549MRQ16.926-3.377
MRQ16.926TTM-7.203+24.130
TTM-7.203YOY114.308-121.512
TTM-7.2035Y33.301-40.504
5Y33.30110Y33.3010.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Merck is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 7.52 means the investor is paying $7.52 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Merck & Company Inc:

  • The EOD is 6.017. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.517. Based on the equity, the company is overpriced. -1
  • The TTM is 7.373. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.017MRQ7.517-1.500
MRQ7.517TTM7.373+0.144
TTM7.373YOY6.622+0.751
TTM7.3735Y7.123+0.250
5Y7.12310Y7.1230.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets112,630,000
Total Liabilities68,982,000
Total Stockholder Equity43,582,000
 As reported
Total Liabilities 68,982,000
Total Stockholder Equity+ 43,582,000
Total Assets = 112,630,000

Assets

Total Assets112,630,000
Total Current Assets38,205,000
Long-term Assets74,425,000
Total Current Assets
Cash And Cash Equivalents 11,304,000
Short-term Investments 50,000
Net Receivables 11,642,000
Inventory 6,469,000
Other Current Assets 8,740,000
Total Current Assets  (as reported)38,205,000
Total Current Assets  (calculated)38,205,000
+/-0
Long-term Assets
Property Plant Equipment 23,221,000
Goodwill 21,161,000
Long Term Investments 357,000
Intangible Assets 16,984,000
Long-term Assets Other 12,702,000
Long-term Assets  (as reported)74,425,000
Long-term Assets  (calculated)74,425,000
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities26,060,000
Long-term Liabilities42,922,000
Total Stockholder Equity43,582,000
Total Current Liabilities
Short Long Term Debt 3,071,000
Accounts payable 3,519,000
Total Current Liabilities  (as reported)26,060,000
Total Current Liabilities  (calculated)6,590,000
+/- 19,470,000
Long-term Liabilities
Long term Debt 34,717,000
Long-term Liabilities Other 7,329,000
Long-term Liabilities  (as reported)42,922,000
Long-term Liabilities  (calculated)42,046,000
+/- 876,000
Total Stockholder Equity
Retained Earnings 60,187,000
Total Stockholder Equity (as reported)43,582,000
Total Stockholder Equity (calculated)60,187,000
+/- 16,605,000
Other
Capital Stock1,788,000
Common Stock Shares Outstanding 2,535,649
Net Debt 26,484,000
Net Invested Capital 81,370,000
Net Working Capital 12,145,000
Property Plant and Equipment Gross 42,181,000



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-30
> Total Assets 
0
0
107,796,000
104,469,000
106,727,000
106,675,000
105,849,000
112,630,000
112,630,000105,849,000106,675,000106,727,000104,469,000107,796,00000
   > Total Current Assets 
33,561,000
35,722,000
33,402,000
29,977,000
31,954,000
32,168,000
31,445,000
38,205,000
38,205,00031,445,00032,168,00031,954,00029,977,00033,402,00035,722,00033,561,000
       Cash And Cash Equivalents 
0
0
9,707,000
5,660,000
8,605,000
6,841,000
5,579,000
11,304,000
11,304,0005,579,0006,841,0008,605,0005,660,0009,707,00000
       Short-term Investments 
0
0
680,000
718,000
168,000
252,000
40,000
50,000
50,00040,000252,000168,000718,000680,00000
       Net Receivables 
10,685,000
10,621,000
10,415,000
12,338,000
10,394,000
10,349,000
11,366,000
11,642,000
11,642,00011,366,00010,349,00010,394,00012,338,00010,415,00010,621,00010,685,000
       Inventory 
5,614,000
5,911,000
5,863,000
5,930,000
6,131,000
6,358,000
6,510,000
6,469,000
6,469,0006,510,0006,358,0006,131,0005,930,0005,863,0005,911,0005,614,000
       Other Current Assets 
6,014,000
5,998,000
6,737,000
5,331,000
6,656,000
8,368,000
7,950,000
8,740,000
8,740,0007,950,0008,368,0006,656,0005,331,0006,737,0005,998,0006,014,000
   > Long-term Assets 
0
0
74,394,000
74,492,000
74,773,000
74,507,000
74,404,000
74,425,000
74,425,00074,404,00074,507,00074,773,00074,492,00074,394,00000
       Property Plant Equipment 
20,424,000
22,768,000
21,758,000
22,231,000
22,526,000
23,051,000
23,045,000
23,221,000
23,221,00023,045,00023,051,00022,526,00022,231,00021,758,00022,768,00020,424,000
       Goodwill 
0
0
21,209,000
21,195,000
21,183,000
21,197,000
21,181,000
21,161,000
21,161,00021,181,00021,197,00021,183,00021,195,00021,209,00000
       Long Term Investments 
0
0
1,290,000
1,214,000
1,306,000
252,000
280,000
357,000
357,000280,000252,0001,306,0001,214,0001,290,00000
       Intangible Assets 
0
0
19,857,000
19,665,000
19,199,000
18,011,000
17,572,000
16,984,000
16,984,00017,572,00018,011,00019,199,00019,665,00019,857,00000
       Long-term Assets Other 
0
0
10,280,000
10,187,000
10,559,000
11,996,000
12,326,000
12,702,000
12,702,00012,326,00011,996,00010,559,00010,187,00010,280,00000
> Total Liabilities 
0
0
60,891,000
65,727,000
65,427,000
69,040,000
65,425,000
68,982,000
68,982,00065,425,00069,040,00065,427,00065,727,00060,891,00000
   > Total Current Liabilities 
22,998,000
24,239,000
23,131,000
23,394,000
23,094,000
25,694,000
25,099,000
26,060,000
26,060,00025,099,00025,694,00023,094,00023,394,00023,131,00024,239,00022,998,000
       Short Long Term Debt 
0
0
2,672,000
2,839,000
887,000
1,372,000
3,077,000
3,071,000
3,071,0003,077,0001,372,000887,0002,839,0002,672,00000
       Accounts payable 
3,973,000
5,037,000
3,680,000
3,905,000
3,509,000
3,922,000
3,514,000
3,519,000
3,519,0003,514,0003,922,0003,509,0003,905,0003,680,0005,037,0003,973,000
       Other Current Liabilities 
4,503,000
4,344,000
0
3,711,000
0
0
0
0
00003,711,00004,344,0004,503,000
   > Long-term Liabilities 
0
0
37,760,000
42,333,000
42,333,000
43,346,000
40,326,000
42,922,000
42,922,00040,326,00043,346,00042,333,00042,333,00037,760,00000
       Long-term Liabilities Other 
0
0
8,244,000
7,265,000
7,343,000
8,792,000
8,262,000
7,329,000
7,329,0008,262,0008,792,0007,343,0007,265,0008,244,00000
> Total Stockholder Equity
0
0
46,834,000
38,693,000
41,246,000
37,581,000
40,364,000
43,582,000
43,582,00040,364,00037,581,00041,246,00038,693,00046,834,00000
   Common Stock
1,788,000
1,788,000
0
1,788,000
0
0
0
0
00001,788,00001,788,0001,788,000
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 00000000
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 0000-4,900,0000-4,768,000-4,743,000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue60,115,000
Cost of Revenue-16,126,000
Gross Profit43,989,00043,989,000
 
Operating Income (+$)
Gross Profit43,989,000
Operating Expense-57,161,000
Operating Income2,954,000-13,172,000
 
Operating Expense (+$)
Research Development30,531,000
Selling General Administrative10,504,000
Selling And Marketing Expenses0
Operating Expense57,161,00041,035,000
 
Net Interest Income (+$)
Interest Income365,000
Interest Expense-1,146,000
Other Finance Cost-0
Net Interest Income-781,000
 
Pretax Income (+$)
Operating Income2,954,000
Net Interest Income-781,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,889,0003,238,000
EBIT - interestExpense = -1,146,000
365,000
1,511,000
Interest Expense1,146,000
Earnings Before Interest and Taxes (EBIT)03,035,000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,889,000
Tax Provision-1,512,000
Net Income From Continuing Ops377,000377,000
Net Income365,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-284,000781,000
 

Technical Analysis of Merck
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Merck. The general trend of Merck is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Merck's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Merck & Company Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 103.91 < 131.30 < 131.30.

The bearish price targets are: 101.50 > 100.09 > 97.24.

Tweet this
Merck & Company Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Merck & Company Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Merck & Company Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Merck & Company Inc. The current macd is -1.75224616.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Merck price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Merck. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Merck price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Merck & Company Inc Daily Moving Average Convergence/Divergence (MACD) ChartMerck & Company Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Merck & Company Inc. The current adx is 13.30.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Merck shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Merck & Company Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Merck & Company Inc. The current sar is 131.30.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Merck & Company Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Merck & Company Inc. The current rsi is 10.40. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Merck & Company Inc Daily Relative Strength Index (RSI) ChartMerck & Company Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Merck & Company Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Merck price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Merck & Company Inc Daily Stochastic Oscillator ChartMerck & Company Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Merck & Company Inc. The current cci is -666.66666667.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Merck & Company Inc Daily Commodity Channel Index (CCI) ChartMerck & Company Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Merck & Company Inc. The current cmo is -94.1717301.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Merck & Company Inc Daily Chande Momentum Oscillator (CMO) ChartMerck & Company Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Merck & Company Inc. The current willr is -92.1475687.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Merck & Company Inc Daily Williams %R ChartMerck & Company Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Merck & Company Inc.

Merck & Company Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Merck & Company Inc. The current atr is 2.65508915.

Merck & Company Inc Daily Average True Range (ATR) ChartMerck & Company Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Merck & Company Inc. The current obv is 2,713,943.

Merck & Company Inc Daily On-Balance Volume (OBV) ChartMerck & Company Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Merck & Company Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Merck & Company Inc Daily Money Flow Index (MFI) ChartMerck & Company Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Merck & Company Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Merck & Company Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Merck & Company Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5010.404
Ma 20Greater thanMa 50129.910
Ma 50Greater thanMa 100129.660
Ma 100Greater thanMa 200124.688
OpenGreater thanClose101.600
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Merck with someone you think should read this too:
  • Are you bullish or bearish on Merck? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Merck? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Merck & Company Inc

I send you an email if I find something interesting about Merck & Company Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Merck & Company Inc.

Receive notifications about Merck & Company Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.